Chiusura precedente | 17,33 |
Aperto | 17,33 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 17,33 - 17,33 |
Intervallo di 52 settimane | 15,78 - 21,88 |
Volume | |
Media Volume | 459 |
Capitalizzazione | 9,319B |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | 24,76 |
EPS (ttm) | 0,70 |
Prossima data utili | 01 ago 2024 - 05 ago 2024 |
Rendimento e dividendo (futuro) | 0,39 (2,26%) |
Data ex dividendo | 27 giu 2024 |
Stima target 1A | N/D |
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a t
Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced